* This chart and data were pulled from the Digital Therapeutics Explainer by Insider Intelligence. Purchase the report here to get immediate access to the full analysis. |
A new class of medicine — digital therapeutics (DTx) — has emerged, offering a novel means of treating the swelling number of patients with chronic diseases and keeping associated costs down.
The surging prevalence of chronic conditions combined with their sky-high price tags is fueling fast growth in the global DTx market, which is poised to expand 21% annually to hit nearly $9 billion by 2025. |
- The sea change sparked by the advent of digital medicines threatens to reshape the entire healthcare value chain. Because drugs interact with nearly every healthcare stakeholder, DTx solutions are causing them to change the way they view disease treatment and make room for digital solutions in their operations.
|
- And while the DTx space is relatively nascent, it has vaulted into the mainstream on the backs of investors and incumbents. Globally, DTx startups secured a total of $400 million in the first half of 2019 — with prominent US-based firms like...
|
|
|
Other report highlights you don’t want to miss… |
| |
| This is just a preview of the information and insights you'll find in the Digital Therapeutics Explainer report by Insider Intelligence. Purchase the report for $495 today to access the full analysis. |
